Drug Sponsors

Arvinas, Merck to collaborate

Wednesday, April 8, 2015 12:41 PM

Arvinas, a New Haven, Conn.-based private biotechnology company creating a new class of drugs based on protein degradation, has formed a strategic collaboration with Merck in which Arvinas' novel PROTAC technology will be used to degrade target proteins to create novel therapeutics. The multi-year collaboration will encompass multiple disease targets across several therapeutic areas.

More... »

Quest Diagnostics

GSK to establish global vaccines R&D center in the U.S.

Monday, April 6, 2015 11:57 AM

GlaxoSmithKline is establishing a new global center for vaccines R&D in Rockville, Md. The site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D center in Rixensart, Belgium and in Siena, Italy, a site GSK acquired from Novartis last month.

More... »


Daiichi Sankyo, Asubio Pharmaceuticals to merge

Friday, April 3, 2015 01:41 PM

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, will merge with its U.S.-based sister company, Asubio Pharmaceuticals. As a result, Asubio Pharmaceuticals projects will be integrated into the Daiichi Sankyo global development organization, led by Mahmoud Ghazzi, M.D., Ph.D.

More... »

TPG completes acquisition of Aptalis, renames company Adare Pharmaceuticals

Thursday, April 2, 2015 01:08 PM

Aptalis Pharmaceutical Technologies has announced that its divestiture from Actavis to TPG, a Texas-based global private investment firm, has been completed. The company also announced its new name is Adare Pharmaceuticals, and John Fraher, who was president of Aptalis Pharmaceutical Technologies, has been named CEO. He is joined by key executives from his current management team.

More... »

Ipsen opens new Massachusetts R&D center

Thursday, April 2, 2015 01:06 PM

Ipsen, a global specialty-driven biotechnological group based in France, has announced the opening of its new R&D center, Ipsen Bioscience, in Cambridge Mass., a U.S. hub for biomedical research and innovation. Ipsen’s strategic decision to invest in the Ipsen Bioscience facility in Cambridge is an important element of the company’s open innovation strategy and its goal of broadening its partnerships with the American biotech, medical and scientific communities.

More... »

Horizon Pharma to acquire Hyperion Therapeutics for $1.1B in cash

Wednesday, April 1, 2015 01:59 PM

Horizon Pharma, based in Ireland, will acquire all of the issued and outstanding shares of California-based Hyperion Therapeutics’ common stock for $46 per share in cash, or approximately $1.1 billion on a fully diluted basis.

More... »

Teva to acquire Auspex for $3.5 billion

Wednesday, April 1, 2015 01:04 PM

Teva Pharmaceutical Industries, headquartered in Israel, and Auspex Pharmaceuticals, based in California, have agreed to merge. Teva will commence a tender offer for all of the outstanding shares of Auspex at $101 per share in cash, for a total of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value.

More... »

Fujifilm to acquire Cellular Dynamics International

Wednesday, April 1, 2015 01:00 PM

Fujifilm, a multinational photography and imaging company headquartered in Tokyo, has entered into a definitive agreement to acquire Cellular Dynamics International (CDI), a developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, via an all-cash tender offer to be followed by a second step merger.

More... »

AcelRx restructures, reduces workforce 36%

Monday, March 30, 2015 02:17 PM

AcelRx Pharmaceuticals, a California-based specialty pharma focused on development and commercialization of innovative therapies for the treatment of acute pain, has restructured its work force as part of a plan to reduce operating costs and focus its financial and development resources on working with the FDA to seek marketing approval for Zalviso, as well as to continue the development of ARX-04.

More... »

Sun Pharma closes merger deal with Ranbaxy

Thursday, March 26, 2015 02:52 PM

Sun Pharmaceutical Industries has begun the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma since the announced merger in April 2014, will focus on supporting strong growth. According to Sun Pharma, the merger has fortified its position as the world's fifth largest specialty generic pharmaceutical company and the top ranking Indian pharma company.

More... »

CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs